SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 29, 2003; DOI 10.1182/blood-2003-03-0759. This Article Full Text (PDF) All Versions of this Article: 2003-03-0759v1 102/6/1943    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bachar-Lustig, E. Articles by Reisner, Y. Search for Related Content PubMed PubMed Citation Articles by Bachar-Lustig, E. Articles by Reisner, Y. Social Bookmarking                   What's this? Submitted March 11, 2003 Accepted May 16, 2003 Anti-third party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose Esther Bachar-Lustig, Shlomit Reich-Zeliger, and Yair Reisner* Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel * Corresponding author; email: yair.reisner{at}weizmann.ac.il. Several bone marrow cells and lymphocyte subpopulations, known as 'veto cells', were shown to induce transplantation tolerance across major histocompatbility antigens. Some of the most potent veto cells are of T cell origin, and in particular a very strong veto activity was documented for CTL lines or clones. However, these cells also possess marked GVH reactivity. In the present study we evaluated a new approach to deplete CTLs of anti-host clones by stimulating the donor T cells against third party stimulators in the absence of exogenous IL-2. We demonstrate that such CTLs are depleted of GVH reactivity while maintaining marked veto activity in vitro. Furthermore, marked synergism was exhibited between the veto CTLs and rapamycin when tested in a murine model which measures T cell mediated bone marrow allograft rejection, or in sublethally irradiated allogeneic hosts. Our results suggest that engraftment of early progenitors could be enhanced by using host non-reactive anti-third party CTLs, in conjunction with non-myeloablative rapamycin based conditioning protocols, thereby significantly reducing the toxicity of allogeneic transplantation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Mariotti, J. Foley, K. Ryan, N. Buxhoeveden, V. Kapoor, S. Amarnath, and D. H. Fowler Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway Blood, December 1, 2008; 112(12): 4765 - 4775. [Abstract] [Full Text] [PDF] J. Mariotti, J. Foley, U. Jung, T. Borenstein, N. Kantardzic, S. Han, J. T. Hanson, E. Wong, N. Buxhoeveden, J. B. Trepel, et al. Ex Vivo Rapamycin Generates Apoptosis-Resistant Donor Th2 Cells That Persist In Vivo and Prevent Hemopoietic Stem Cell Graft Rejection J. Immunol., January 1, 2008; 180(1): 89 - 105. [Abstract] [Full Text] [PDF] S. Reich-Zeliger, E. Bachar-Lustig, A. Bar-Ilan, and Y. Reisner Tolerance Induction in Presensitized Bone Marrow Recipients by Veto CTLs: Effective Deletion of Host Anti-Donor Memory Effector Cells J. Immunol., November 15, 2007; 179(10): 6389 - 6394. [Abstract] [Full Text] [PDF] S. Reich-Zeliger, E. Bachar-Lustig, J. Gan, and Y. Reisner Tolerance Induction by Veto CTLs in the TCR Transgenic 2C Mouse Model. I. Relative Reactivity of Different Veto Cells J. Immunol., December 1, 2004; 173(11): 6654 - 6659. [Abstract] [Full Text] [PDF] B. J. Chen, X. Cui, G. D. Sempowski, C. Liu, and N. J. Chao Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease Blood, February 15, 2004; 103(4): 1534 - 1541. [Abstract] [Full Text] [PDF] Minerva BMJ, September 27, 2003; 327(7417): 758 - 758. [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020